News

People experiencing homelessness exhibit similar rates of morbidity compared with housed patients, but a longer adjusted length of hospital stay.

In honor of Rare Disease Day, this exploration of prurigo nodularis highlights the skin disease’s psychosocial impact on patients around the world living with the condition.

Cancer patients with behavioral health disorders, such as substance abuse, eating disorders, and sleep disorders have a 7.76% increase in health care costs, a new study found.

Positive topline results show apraglutide outperformed placebo for relative change from baseline in actual weekly parenteral support volume at week 24 in adults with SBS-IF.

This analysis presented at AAAAI suggests that the experimental OMIT delivery of allergens via toothpaste may allow for a safer alternative to other immunotherapies.

A new study found only 15% of people sleep the recommended 7 – 9 hours for ≥ 5 nights per week.

Our February 2024 month in review highlights EoE pipeline news, new FMT guidelines, and research about endoscopic inflammation and disease activity in IBD.

Hosts breakdown a pair of recent publications related to better understanding the strengths and limitations of MARD as well as a study comparing the Dexcom G7 and FreeStyle Libre 3 sensors.

Inflammatory markers, infliximab levels, and physician global assessment scores remained similar when assessed pre- and post-switch to an infliximab biosimilar.

Viking Therapeutics' dual GLP-1/GIP receptor agonist VK2735 showed promising weight reduction in the phase 2 VENTURE trial, with the 15 mg dose contributing to a 14% reduction in body weight from baseline to week 13.

This analysis emphasizes the necessity of prevention of melanoma as well as the public health and economic consequences of patients’ delaying of skin cancer diagnoses.

MoodCapture, an app with AI that can detect depression onset from facial cues, accurately diagnosed 75% of participants in a study with early symptoms of depression.

Dubinsky discusses the importance of head-to-head trials in IBD and looks ahead to the use of combination therapy to achieve desired treatment outcomes.

Hosts break down their favorite sessions at the upcoming 17th International Conference on Advanced Technologies and Treatments for Diabetes.

Deepak Bhatt, MD, MPH, looks ahead to discuss what he is most excited about from the upcoming late-breaking clinical trials sessions at the American College of Cardiology 2024 annual meeting

In this Q&A discussion, Bhatt discusses the recent news of dupilumab’s supplemental Biologics License Application for COPD patients with type 2 inflammation, as well as its significance.

Brassica Pharma Pvt. Ltd. is voluntarily recalling eye ointment products with expiration dates from February 2024 to September 2025.

Results suggest a high prevalence of fatty liver in adults with chronic HCV, which was significantly associated with central obesity, elevated blood pressure, and metabolic syndrome.

These new data from BioCryst, presented at AAAAI, suggest that patients treated with berotralstat may see substantial decreases in HAE attacks.

Minerva Neurosciences announced the receipt of a Complete Response Letter for roluperidone in treatment of negative symptoms in patients with schizophrenia on February 27, 2024 despite clinical trial data indicating improved Negative Symptom Factor Scores and Personal and Social Performance scale scores.

After observing for sex differences, plant-based diet indices were associated with lower odds of OSA risk in males than females.

Viaskin milk patch shows promise in cow’s milk allergy, particularly in children aged 2-11 with 300 μg dose, though the other doses examined failed to prove significant benefit.

Younger gestational age, lower birthweight, and a more severe initial AKI episode were identified as risk factors for recurrent AKI, which was linked to extended hospitalization.

Introduction of curated materials to assist clinicians was linked to better rates of screening and treatment of iron deficiency anemia among patients with heart failure.

Twelve evidence-based Key Action Statements were provided for clinicians to guide them in the treatment of patients reporting inhalant allergy symptoms.

An ancillary study of the phase 2 HOPE-KIDS 1 trial revealed voxelotor is associated with reduced sickling and hemolysis in children with SCD.

In an interview during the 2024 AAAAI conference, Casale addressed his team’s findings regarding epinephrine nasal spray and its effectiveness with regard to exacerbations of urticaria.

The approval was based on clinical data from 3 multicenter, randomized trials which demonstrated the safety, efficacy, and biosimilarity of adalimumab-ryvk compared with the reference product.